LARGO, Fla., Jan. 22 /PRNewswire-FirstCall/ -- In an effort to continue to communicate precisely who we are and what we do, GeoPharma, Inc. has decided to issue this expanded corporate profile to reflect its recent acquisition and other new additions to its business model.
Company Profile:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
The Specialty Pharma segment is composed of GeoPharma subsidiaries, Belcher Pharmaceuticals, Inc. and American Antibiotics, Inc. Belcher is a state-of-the-art 50,000 Sq. Ft. FDA-registered manufacturing, research and development facility designed to produce generic drugs and Cephalosporins. American Antibiotics is a Beta-Lactam facility dedicated to Amoxicillin, Ampicillin, and Penicillin production. American Antibiotics operates out of 100,000 Square Feet in Baltimore, Maryland. GeoPharma recently received FDA approval to manufacture Carprofen, a generic veterinary drug used to treat arthritis in dogs. GeoPharma also announced it has acquired the rights to a diagnostic technology for early stage detection of ovarian cancer. Additionally, GeoPharma's drug pipeline contains 12 ANDA's and other drug products, several of these initiatives are pending approval and process completion.
The Manufacturing segment is highlighted by GeoPharma's other subsidiaries Libi Labs, Inc., Innovative Health Products, Inc. and EZ-Med Technologies, Inc. Libi Labs primary focus is cosmeceuticals, while Innovative Health Products handles the bulk of GeoPharma's contract manufacturing business. EZ- Med Technologies uses its own patented soft-chew technology to manufacture companion animal nutritional supplements.
The Distribution segment showcases the GeoPharma subsidiaries Breakthrough Engineered Nutrition, Inc. and Bob O'Leary Health Food Distributor Co., Inc. (BOSS). Breakthrough develops markets and distributes GeoPharma's own branded dietary supplements. BOSS, is a full line leading distributor of Sports Nutrition products, Dietary Supplements, and Performance Beverages. BOSS distributes products manufactured by over 100 vendors, including top health food and nutrition brands such as Iovate, EAS, VPX, BSN, and Cytosport. Both Breakthrough and Boss products are distributed nationwide and internationally in specialty stores and mass outlets, including Target, Wal-Mart, GNC, Walgreens, CVS, Rite Aid, Duane Reade and many others.
GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.
Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq Ft. of office, warehouse, manufacturing and laboratory facilities.
For further information visit the "For Investors" section of the GeoPharma website at www.geopharmainc.com
Safe Harbor Statement: This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
IR@GeoPharmainc.com
CONTACT: Alexander Nachman, Director of Investor and Media Relations of
GeoPharma, Inc, +1-727-471-0850 x243, IR@GeoPharmainc.com
Web site: http://www.geopharmainc.com/